KeyCorp Estimates Solventum’s FY2026 Earnings (NYSE:SOLV)

Solventum Corporation (NYSE:SOLV) – Equities researchers at KeyCorp cut their FY2026 EPS estimates for shares of Solventum in a research note issued to investors on Sunday, January 25th. KeyCorp analyst B. Fishbin now forecasts that the company will earn $6.20 per share for the year, down from their previous forecast of $6.30. KeyCorp currently has a “Overweight” rating and a $97.00 target price on the stock. The consensus estimate for Solventum’s current full-year earnings is $6.58 per share.

A number of other brokerages have also recently commented on SOLV. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Mizuho set a $100.00 price target on shares of Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $90.83.

Solventum Trading Down 1.9%

Shares of SOLV stock opened at $77.51 on Wednesday. The company has a market cap of $13.44 billion, a price-to-earnings ratio of 8.93, a PEG ratio of 7.23 and a beta of 0.34. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The firm has a fifty day moving average price of $81.72 and a 200-day moving average price of $75.77. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the prior year, the company earned $1.64 earnings per share. The firm’s revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS.

Institutional Trading of Solventum

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Independent Franchise Partners LLP grew its position in shares of Solventum by 74.2% during the second quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock valued at $769,098,000 after purchasing an additional 4,320,342 shares in the last quarter. Norges Bank bought a new position in Solventum during the second quarter valued at approximately $140,495,000. Boston Partners grew its holdings in Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares in the last quarter. Vanguard Group Inc. increased its stake in Solventum by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after acquiring an additional 867,837 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Solventum during the 3rd quarter worth approximately $42,393,000.

Solventum declared that its board has approved a share repurchase plan on Thursday, November 20th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to purchase up to 7.5% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.